Methodology

All entries for: Merck Sharp & Dohme LLC.

June 6, 2026

Merck Sharp & Dohme LLC.

Orphan Drug Designation

treatment of neuroendocrine prostate cancer (NEPC)

Disease Area: Rare Diseases
Source
Scroll to Top